Stock Events

Stock Events

Trevena 

$0.001000
64
-$0.01-90.99% Wednesday 15:36

Statistics

Day High
0.012
Day Low
0.012
52W High
1.14
52W Low
0.001
Volume
210
Avg. Volume
174
Mkt Cap
864
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

8MayExpected
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Q3 2024
Q1 2025
-10.13
-6.8
-3.48
-0.15
Expected EPS
-0.37
Actual EPS
N/A

Financials

-1,289.25%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
6.25MRevenue
-80.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRVN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.61B
ACADIA Pharmaceuticals competes with Trevena in the development of central nervous system therapies, including treatments for pain and other conditions Trevena targets.
Alkermes
ALKS
Mkt Cap7.39B
Alkermes competes in the area of central nervous system diseases, offering products that could be in direct competition with Trevena's pipeline.
Johnson & Johnson
JNJ
Mkt Cap579.83B
Johnson & Johnson, through its pharmaceutical division Janssen, develops medications that can compete with Trevena's offerings, especially in pain management.
Novartis
NVS
Mkt Cap292.07B
Novartis offers a broad range of healthcare solutions, including treatments for chronic pain and neurological conditions, areas Trevena is involved in.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap40.32B
Teva Pharmaceutical Industries is a key player in generic and specialty medicines, including pain management, directly competing with Trevena's market.
Abbvie
ABBV
Mkt Cap402.35B
AbbVie has a strong presence in the neuroscience and pain management sectors, making it a competitor to Trevena's therapeutic focus.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol Myers Squibb develops a wide range of prescription drugs, including those for conditions Trevena targets, making them competitors.
Pfizer
PFE
Mkt Cap149.38B
Pfizer's extensive portfolio in pain management and neurological disorders places it in direct competition with Trevena's product pipeline.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. offers innovative health solutions, including treatments for pain and neurological conditions, competing with Trevena.

About

Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.
Show more...
CEO
Ms. Carrie L. Bourdow
Employees
23
Country
United States
ISIN
US89532E3071

Listings

STU
DE
6T4.STU
MU
DE
6T4.MU
OTC Link
US
TRVN

0 Comments

Share your thoughts

FAQ

What is Trevena stock price today?▼
The current price of TRVN is $0.00 USD — it has decreased by -90.99% in the past 24 hours. Watch Trevena stock price performance more closely on the chart.
What is Trevena stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Trevena stocks are traded under the ticker TRVN.
Is Trevena stock price growing?▼
TRVN stock has fallen by -90.91% compared to the previous week, the month change is a -90.91% fall, over the last year Trevena has showed a -99.91% decrease.
What is Trevena market cap?▼
Today Trevena has the market capitalization of 864
What is Trevena revenue for the last year?▼
Trevena revenue for the last year amounts to 6.25M USD.
What is Trevena net income for the last year?▼
TRVN net income for the last year is -80.58M USD.
How many employees does Trevena have?▼
As of June 18, 2026, the company has 23 employees.
In which sector is Trevena located?▼
Trevena operates in the Health & Wellness sector.
When did Trevena complete a stock split?▼
The last stock split for Trevena was on August 13, 2024 with a ratio of 1:25.
Where is Trevena headquartered?▼
Trevena is headquartered in Chesterbrook, United States.